University of Colorado

The trials here

What the 34 trials at this site are about, from their registry records.

Conditions

• Lung cancer7 trials
• Melanoma4 trials
• Myotonic dystrophy3 trials
• Pancreatic cancer3 trials
• Acute myeloid leukaemia2 trials
• Friedreich ataxia2 trials
• Vascular dementia2 trials
• ALS (motor neurone disease)1 trial
• Bladder cancer1 trial
• Cervical cancer1 trial
• Childhood cancers1 trial
• Colorectal cancer1 trial
• and 14 more

Phase

• Phase 29 trials
• Phase 35 trials
• Phase 2/32 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Completed11 trials
• Active, not recruiting9 trials
• Recruiting8 trials
• Enrolling by invitation3 trials
• Terminated3 trials

Lead sponsor

• Avidity Biosciences, Inc.3 trials
• M.D. Anderson Cancer Center3 trials
• Alliance for Clinical Trials in Oncology2 trials
• Friedreich's Ataxia Research Alliance2 trials
• Northwestern University2 trials
• and 22 more

Running trials

• Recruiting

  A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

  NCT06624644· Phase 2/3· Linnaeus Therapeutics, Inc.· Source

  Contact: Kathy Prinz

• Enrolling by invitation

  Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

  NCT07008469· Phase 3· Avidity Biosciences, Inc.· Source

• Active, not recruiting

  RADIQAL Study (Radiation Dose and Image Quality Trial)

  NCT06944509· Philips Clinical & Medical Affairs Global· Source

• Enrolling by invitation

  Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening Accuracies

  NCT06144229· University of California, Los Angeles· Source

• Recruiting

  Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

  NCT06016946· Friedreich's Ataxia Research Alliance· Source

  Contact: Dillan Patel

• Recruiting

  DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

  NCT05701917· Inari Medical· Source

  Contact: Jonathan D Lindquist, MD

• Active, not recruiting

  A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

  NCT05608044· Phase 2· Agenus Inc.· Source

• Recruiting

  PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.

  NCT05306743· Observational and Pragmatic Research Institute· Source

  Contact: Rodger Kessler, PhD

• Recruiting

  Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study

  NCT05677880· University of Wisconsin, Madison· Source

  Contact: Cadasil Consortium

• Enrolling by invitation

  Long-Term Follow-up Study

  NCT05332054· Caribou Biosciences, Inc.· Source

• Active, not recruiting

  Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

  NCT04576104· Phase 2· Northwestern University· Source

• Active, not recruiting

  Chronic Pain in Rheumatoid Arthritis

  NCT05038553· Northwestern University· Source

• Recruiting

  Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

  NCT06651580· M.D. Anderson Cancer Center· Source

  Contact: Jacob Mark

• Recruiting

  Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY

  NCT04916210· Massachusetts General Hospital· Source

  Contact: Jennifer Simpson, MD

• Active, not recruiting

  Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

  NCT03891784· Phase 2· University of Washington· Source

• Active, not recruiting

  Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

  NCT03410043· Phase 2· M.D. Anderson Cancer Center· Source

• Recruiting

  American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

  NCT02674100· University of Louisville· Source

  Contact: Ana Gleisner

• Active, not recruiting

  Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

  NCT01892397· Memorial Sloan Kettering Cancer Center· Source

• Active, not recruiting

  Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

  NCT00499330· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  FA Clinical Outcome Measures

  NCT03090789· Friedreich's Ataxia Research Alliance· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Pancreatic cancer2 recruiting
• Vascular dementia2 recruiting
• Acute myeloid leukaemia1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• COPD1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Friedreich ataxia1 recruiting
• HIV1 recruiting
• Melanoma1 recruiting
• Mild cognitive impairment1 recruiting
• Multiple myeloma1 recruiting
• Myotonic dystrophy1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  Global Study of Del-desiran for the Treatment of DM1

  NCT06411288· Phase 3· Avidity Biosciences, Inc.· Source

• Completed

  Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

  NCT05479981· Phase 2· Avidity Biosciences, Inc.· Source

• Terminated

  Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

  NCT04935229· Phase 1· TriSalus Life Sciences, Inc.· Source

• Completed

  Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

  NCT04259255· Shionogi· Source

• Terminated

  Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

  NCT03645928· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

  NCT03815058· Phase 2· Genentech, Inc.· Source

• Completed

  A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

  NCT03474107· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Characterization and Treatment of Adolescent Depression

  NCT03388606· National Institute of Mental Health (NIMH)· Source

  Contact: Daniel S Pine, M.D.

• Terminated

  Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

  NCT03148327· Phase 1/2· Jonsson Comprehensive Cancer Center· Source

• Recruiting

  Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

  NCT03013998· Phase 2/3· Beat AML, LLC· Source

  Contact: Ashley Yocum, PhD

• Completed

  Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

  NCT01725165· Phase 2· M.D. Anderson Cancer Center· Source

• Completed

  Scleroderma Treatment With Autologous Transplant (STAT) Study

  NCT01413100· Phase 2· Fred Hutchinson Cancer Center· Source

• Completed

  Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source